Thermoresponsive Zinc TetraPhenylPorphyrin Photosensitizer/Dextran Graft Poly(N-IsoPropylAcrylAmide) Copolymer/Au Nanoparticles Hybrid Nanosystem: Potential for Photodynamic Therapy Applications.

The thermoresponsive Zinc TetraPhenylPorphyrin photosensitizer/Dextran poly (N-isopropylacrylamide) graft copolymer/Au Nanoparticles (ZnTPP/D-g-PNIPAM/AuNPs) triple hybrid nanosystem was synthesized in aqueous solution as a nanodrug for potential use in thermally driven and controlled photodynamic therapy applications. The aqueous solution of the nanosystem has demonstrated excellent stability in terms of aggregation and sedimentation several days after preparation. Optimal concentrations of the components of hybrid nanosystem providing the lowest level of aggregation and the highest plasmonic enhancement of electronic processes in the photosensitizer molecules have been determined. It has been revealed that the shrinking of D-g-PNIPAM macromolecule during a thermally induced phase transition leads to the release of both ZnTPP molecules and Au NPs from the ZnTPP/D-g-PNIPAM/AuNPs macromolecule and the strengthening of plasmonic enhancement of the electronic processes in ZnTPP molecules bound with the polymer macromolecule. The 2.7-fold enhancement of singlet oxygen photogeneration under resonant with surface plasmon resonance has been observed for ZnTPP/D-g-PNIPAM/AuNPs proving the plasmon nature of such effect. The data obtained in vitro on wild strains of Staphylococcus aureus have proved the high potential of such nanosystem for rapid photodynamic inactivation of microorganisms particular in wounds or ulcers on the body surface.

Plasmonic enhancement of the antibacterial photodynamic efficiency of a zinc tetraphenylporphyrin photosensitizer/dextran graft polyacrylamide anionic copolymer/Au nanoparticles hybrid nanosystem.

A zinc tetraphenylporphyrin photosensitizer/dextran graft polyacrylamide anionic copolymer/Au nanoparticles (ZnTPP/D-g-PAAan/AuNPs) triple hybrid nanosystem was synthesized in water-based solution as a nanodrug for potential photodynamic therapy applications. Dynamic light scattering studies showed that the nanosystem is stable against aggregation and sedimentation for several days after preparation. The dependence of the ZnTPP fluorescence intensity on the gold concentration in the ZnTPP/D-g-PAAan/AuNPs nanosystem has been revealed to be non-monotonic, with a maximum 2.5-fold enhancement at a concentration of 0.008 g L-1. The non-monotonic dependence was explained to be caused by two competing processes, namely plasmonic enhancement and FRET, indicating the existence of an optimal concentration of Au NPs that can provide the highest plasmonic enhancement of the electronic processes involving the ZnTPP photosensitizer. A 2.6-fold enhancement of singlet oxygen photogeneration under excitation resonant with the localized surface plasmon resonance of the Au NPs has been detected for ZnTPP/D-g-PAAan/AuNPs, proving the plasmonic origin of this phenomenon. The high bactericidal efficiency of ZnTPP/D-g-PAAan/AuNPs water-based solution under 420 nm and 530 nm light irradiation was revealed against wild strains of Staphylococcus aureus. Therefore, the ZnTPP/D-g-PAAan/AuNPs nanosystem can potentially be used in photodynamic therapy for the prevention and treatment of the bacterial contamination of open wounds.

Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine.

We have demonstrated the influence of cerium dioxide nanoparticles on the immunogenicity of the influenza vaccine on an example of liquid split inactivated Vaxigrip vaccine. Antibody titers were analyzed using the hemagglutination inhibition (HI) assay. Seroprotection, seroconversion, the geometric mean titers (GMTs) and the factor increase (FI) in the GMTs were calculated. The effect of nano-ceria surface stabilizer on the enhancement of immunogenicity was shown. The vaccine modified by citrate-stabilized nano-ceria, in contrast to a non-modified Vaxigrip vaccine, did not provide an adequate level of seroprotection, and seroconversion after vaccination was 66.7% on days 49-63 for virus strain А(H1N1) and 100% on day 49 for virus strain B/Yamagata. For the low immunogenic influenza B virus, the rise in antibody titers (GMT/IF) was 24.38/3.28 after the first injection and 50.40/6.79 on day 49. For the vaccine modified by non-stabilized nano-ceria, for all virus strains under study, on day 63, upon immunization notable levels of seroprotection, seroconversion and GMT/IF were registered (higher than for the non-modified Vaxigrip vaccine). The successful attempt to modify the influenza vaccine demonstrates the possible ways of increasing the specific activity of vaccines using nano-ceria.